Pharmageddon

Pharmageddon

Volumn , Issue , 2012, Pages

  Healy, David ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84862165832     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (346)

1. Joseph T. Freeman, Dr. Alfred J. Worcester: Early exponent of modern geriatrics, Bulletin NY Academy of Medicine 64, 246-251 (1988)
2. Derek Kerr, Alfred Worcester: A pioneer in palliative care, American Journal of Hospice and Palliative Care, May, 13-36 (1992)
3. Charles Crenner, Private Practice. The Early Twentieth-Century Medical Office of Dr. Richard Cabot (Baltimore: Johns Hopkins University Press, 2006)
4. Ivan Illich, Medical Nemesis: The Limits of Medicine (London: Calder and Boyars, 1975)
5. Charles Medawar, Graham Dukes, Tim Reed, Andrew Herxheimer, and David Healy, "Pharmageddon," http://www.socialaudit.org.uk/60700716.htm#Pharmageddon (accessed July 30, 2007)
6. Jason Lazarou, Bruce H. Pomeranz, and Paul N. Corey, Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies, JAMA 279, 1200-1205 (1998)
7. John Abramson, Overdosed America: The Broken Promise of American Medicine (New York: Harper Perennial, 2004)
8. Jerome Kassirer, On the Take (New York: Oxford University Press, 2006)
9. Marcia Angell, The Truth about the Drug Companies (New York: Random House, 2006)
10. Merrill Goozner, The $800 Million Pill (Berkeley: University of California Press, 2004)
11. Sheldon Krimsky, Science in the Private Interest (Lanham, MD: Rowman and Littlefield, 2004)
12. Ray Moynihan and Alan Cassels, Selling Sickness (New York: Nation Books, 2005)
13. Jeremy Greene, Prescribing by Numbers (Baltimore: Johns Hopkins University Press, 2007)
14. Alicia Mundy, Dispensing with the Truth (New York: St. Martin's Press, 2003)
15. Abramson, Overdosed America; Melody Petersen, Our Daily Meds (New York: Farrar, Straus and Giroux, 2008)
16. Alison Bass, Side Effects (Chapel Hill, NC: Algonquin, 2008)
17. Hank McKinnell, A Call to Action (New York: McGraw Hill, 2005)
18. Daniel Callahan and Angela A. Wasunna, Medicine and the Market: Equity v. Choice. (Baltimore: Johns Hopkins University Press, 2006)
19. Philippe Pinel (1809), Traité médico-philosophique sur l'aliénation mentale, in Treatise on Mental Alienation, trans. Gordon Hickish, David Healy, and Louis Charland, xiii (Chichester: John Wiley and Sons, 2009)
20. Kalman Applbaum, "Marketing Global Healthcare: The Practices of Big Pharma," Socialist Register, http://www.mcareol.com/mcolfree/mcolfre1/visiongain/blockbuster.htm (accessed June 17, 2008)
21. Alfred Worcester, Past and present methods in the practice of medicine, Boston Medical and Surgical Journal 166, 159-164 (1912)
22. Arthur Kleinman, The Illness Narratives (New York: Basic Books, 1988)
23. Michael Oldani, Filling Scripts: A Multi-Sited Ethnography of Pharmaceuticals Sales Practices, Psychiatric Prescribing, and Phamily Life in North America (PhD dissertation, Princeton University, 2006)
24. Hank McKinnell, A Call to Action (New York: McGraw Hill, 2005)
25. Charles C. Mann and Mark L. Plummer, The Aspirin Wars (New York: Alfred A. Knopf, 1991)
26. Kalman Applbaum, The Marketing Era (New York: Routledge, 2004)
27. Applbaum, The Marketing Era. See also Kalman Applbaum, Pharmaceutical marketing and the invention of the medical consumer, PLoS Medicine 3, e189 (2006)
28. Joseph Liebenau, Medical Science and Medical Industry (Basingstoke: Macmillan Press, 1987)
29. James H. Young, The Medical Messiahs: The Social History of Health Quackery in Twentieth-Century America (Princeton: Princeton University Press, 1992)
30. British Medical Association, Secret Remedies (London: British Medical Association, 1909)
31. Charles E. Rosenberg, "The Therapeutic Revolution: Medicine, Meaning and Social Change in Nineteenth-Century America," in The Therapeutic Revolution, ed. M. J. Vogel and C. E. Rosenberg, 3-25 (Philadelphia: University of Pennsylvania Press, 1979)
32. Liebenau, Medical Science and Medical Industry; P. J. Hilts, Protecting America's Health: The FDA, Business and One Hundred Years of Regulation (New York: Alfred A. Knopf, 2003)
33. Edward S. Shorter, "Primary Care," in The Cambridge Illustrated History of Medicine, ed. Roy Porter (Cambridge: Cambridge University Press, 1996)
34. Frank D. Prager, The early growth and influence of intellectual property, Journal of the Patent Office Society 34, 106-140 (1952)
35. Christine MacLeod, Inventing the Industrial Revolution. The English Patent System, 1660-1800 (Cambridge: Cambridge University Press, 1988)
36. Peter Drahos and John Braithwaite, Information Feudalism: Who Owns the Knowledge Economy? (London: Earthscan, 2002)
37. Jean-Paul Gaudilliere, How pharmaceuticals became patentable: The production and appropriation of drugs in the twentieth century, History and Technology 24, 99-106 (2008)
38. Maurice Cassier, Brevets pharmaceutiques et sante publique en France, Enterprise et histoire 36, 29-47 (2004)
39. Michael Bliss, The Discovery of Insulin (Toronto: McClelland and Stewart, 1982)
40. David Healy, The Antidepressant Era, chap. 2 (Cambridge, MA: Harvard University Press, 1998)
41. David Healy, Let Them Eat Prozac (New York: New York University Press, 2004)
42. David Healy, "From Mania to Bipolar Disorder," in Bipolar Disorder, ed. Y. Latham and M. Maj (Chichester: John Wiley and Sons, 2009)
43. Shankar Vedantam, "Suicide risk tests for teens debated," Washington Post, June 16, 2006.
44. Shankar Vedantam, "The depressionist," Washington Post, May 26, 2009.
45. David Sheahan, "Angles on panic," in The Psychopharmacologists, ed. David Healy, 3, 479-504 (London: Arnold, 2000)
46. Thomas Hage, The Demon under the Microscope (New York: Harmony Books, 2006)
47. Richard Harris, The Real Voice (New York: Macmillan Press, 1964), 13.
48. Alexis Jetter, "Pregnant pause," Vogue, May 2009, 144-146.
49. American Medical Association, Nostrums and Quackery (Washington, DC: American Medical Association Press, 1912)
50. Steven R. Belenko, Drugs and Drug Policy in America (Westport: Greenwood Press, 2000)
51. David F. Musto, The American Disease: Origins of Narcotic Control (New York: Oxford University Press, 1987)
52. Steven B. Karch, A Brief History of Cocaine (Boca Raton, FL: CRC Press, 1998)
53. Leo Meyler, Side Effects of Drugs (New York: Elsevier, 1952)
54. Philip Knightley, Harold Evans, E. Potter, and M. Wallace, Suffer the Children: The Story of Thalidomide (London: Andrew Deutsch, 1979)
55. Peter Temin, Taking Your Medicine: Drug Regulation in the United States (Cambridge, MA: Harvard University Press, 1980)
56. C. Robin Ganellin, "Cimetidine," in Chronicles of Drug Discovery, ed. Jasjit S. Bindra and Daniel Lednicer, 1-37 (New York: John Wiley and Sons, 1990)
57. Matthew Lynn, The Billion-Dollar Battle: Merck v Glaxo (London: Mandarin, 1991)
58. Barry J. Marshall (ed.), Helicobacter Pioneers (Carlton South: Blackwell, 2002)
59. Christoph U. Correll et al., Cardiometabolic risk of secondgeneration antipsychotic medications during first-time use in children and adolescents, JAMA 302, 1765-1773 (2009)
60. Christopher K. Varley and Jon McClellan, Implications of marked weight gain associated with atypical ntipsychotic medications in children and adolescents, JAMA 302, 1811-1812 (2009)
61. Terence Young, Death by Prescription (Toronto: Key Porter Books, 2001)
62. Edward Shorter, From Paralysis to Fatigue: A History of Psychosomatic Illness in the Modern Era, 311-313 (New York: Free Press, 1992)
63. Francoise Simon and Philip Kotler, Building Global Biobrands, 147 (New York: Free Press, 2003)
64. Julie M. Donohue, Merisa Cavasco, and Meredith B. Rosenthal, A decade of direct-to-consumer advertising of prescription drugs, New England Journal of Medicine 357, 673-681 (1991)
65. Glen Spielmans, Duloxetine does not relieve painful physical symptoms in depression: A meta-analysis, Psychotherapy and Psychosomatics 77, 12-16 (2008)
66. George Ashcroft, "The receptor enters psychiatry," in The Psychopharmacologists, ed. David Healy, 3, 189-200 (London: Arnold, 2000)
67. Jeremy Greene, Prescribing by Numbers (Baltimore: Johns Hopkins University Press, 2007)
68. Steven Woloshin and Lisa M. Schwartz, Giving legs to restless legs: A case study of how the media makes people sick, PLoS Medicine 3, 170-174 (2006), doi:10.1371/journal.pmed.0030170.
69. Peter Kramer, Listening to Prozac (New York: Viking Press, 1993)
70. E. Fuller Torrey, The going rate on shrinks: Big pharma and the buying of psychiatry, The American Prospect, 15-16 (July 2002)
71. Daniel Bell, The cultural contradictions of capitalism (New York: Basic Books, 1995)
72. Thomas Franks, Commodify your Dissent (New York: Norton, 1999)
73. Joseph Heath and Andrew Potter, The Rebel Sell: How the Counterculture Became Consumer Culture (Chichester: Capstone, 2005)
74. Dora B. Weiner, The Citizen-Patient in Revolutionary and Imperial Paris (Baltimore: Johns Hopkins University Press, 2002)
75. Laurie Garrett, Betrayal of Trust: The Collapse of Global Public Health (New York: Hyperion, 2000)
76. Merrill Goozner, The $800 Million Pill (Berkeley: University of California Press, 2004)
77. British Medical Association, Secret Remedies (London: British Medical Association, 1909)
78. John H. Coverdale, Laurence B. McCullagh, and Frank A. Chervenak, The ethics of randomized placebo controlled trials of antidepressants with pregnancy women: A systematic review, Obstetrics and Gynecology 112, 1361-1368 (2008)
79. Anne Drapkin Lyerly et al., Risk and pregnant body, Hastings Center Report 39, 34-42 (2009)
80. David Healy, Derelie Mangin, and Barbara Mintzes, The ethics of randomized placebo controlled trials of antidepressants with pregnant women, International Journal of Risk and Safety in Medicine 22, 1-10 (2010), doi:10.3233/JRS-2010-0487.
81. Jason Dana and George Loewenstein, A social science perspective on gifts to physicians from industry, JAMA 290: 2, 252-255 (2003)
82. Michael A. Steinman, Michael G. Shlipak, and Steven J. McPhee, Of principles and pens: Attitudes of medicine house stafftoward pharmaceutical industry promotions, American Journal of Medicine, 110, 551-557 (2001)
83. Meredith Wadman, The senator's sleuth, Nature 461, 330-33 (Sept. 17, 2009)
84. James Lind, A Treatise of the Scurvy (1752; Edinburgh: Edinburgh University Press, 1953), 145.
85. Philippe Pinel, Traité médico-philosophique sur la manie (1800), trans. D. Davis (London: Cadell and Davies, 1806)
86. Philippe Pinel, Traité médico-philosophique sur l'aliénation mentale (1809), trans. Gordon Hickish, David Healy, and Louis C. Charland (Chichester: John Wiley and Sons, 2009)
87. Pierre C. A. Louis, cited in A. M. Lilienfeld, Ceteribus paribus: The evolution of the clinical trial, Bulletin of the History of Medicine 56, 1-18, 6 (1982)
88. Pierre C. A. Louis, cited in M. D. Rawlins, Development of a rational practice of therapeutics, BMJ 301, 729-733 (1990)
89. Roy Porter, The Greatest Benefit to Mankind (London: Fontana Press, 1999)
90. Martha Marquardt, Paul Ehrlich (New York: Henry Schumann, 1951)
91. Paul De Kruif, Microbe Hunters (New York: Harcourt, 1926)
92. Sandra Hempel, The Strange Case of the Broad Street Pump: John Snow and the Mystery of Cholera (Berkeley: University of California Press, 2009)
93. Lawrence Altman, Who Goes First? The Story of Self-Experimentation in Medicine (New York: Random House, 1987)
94. Sanjeebit J. Jachuk, H. Brierley, S. Jachuk and P. M. Willcox, The effect of hypotensive drugs on the quality of life, Journal of the Royal College of General Practitioners 32, 103-105 (1982)
95. Ronald Fisher, The Design of Experiments (Edinburgh: Oliver and Boyd, 1935)
96. Steven T. Ziliak and Deirdre N. McCloskey, The Cult of Statistical Significance: How the Standard Error Cost Us Jobs, Justice and Lives (Ann Arbor: University of Michigan Press, 2008)
97. Gordon C. Smith and Jill P. Pell, Parachute use to prevent death and major trauma related to gravitational challenge, BMJ 327, 1459-1461 (2003)
98. Thomas Hager, The Demon under the Microscope (New York: Harmony Books, 2006)
99. Marc A. Pfeffer, Emmanuel A. Burdmann, Chao-Yin Chen et al., A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease and anemia, NEJM 361 (2009), doi:10.1056/NEJMoa0907845.
100. Philip A. Marsden, Treatment of anemia in chronic kidney disease: Strategies based on evidence, NEJM 361 (2009), doi:10.1056/NEJMe0909664.
101. Bruce M. Psaty and Richard A. Kronmal, Reporting mortality findings in trials of rofecoxib forAlzheimer disease or cognitive impairment, JAMA 299, 1813-1817 (2008)
102. Harry Collins and Trevor Pinch, Dr. Golem. How to Think about Medicine (Chicago: University of Chicago Press 2005)
103. Mary Robertson and Michael Trimble, Major tranquilizers used as antidepressants, J Affective Disorders 4, 173-193 (1982)
104. David Healy, Let Them Eat Prozac (New York: New York University Press, 2004)
105. David Healy, The assessment of outcome in depression: Measures of social functioning, Reviews in Contemporary Pharmacotherapy 11, 295-301 (2000)
106. Daniel Kahnemann, Paul Slovic, and Amos Tversky, Judgment under Uncertainty: Heuristics and Biases (Cambridge: Cambridge University Press, 1982)
107. Joseph F. Wernicke et al., Low-dose fluoxetine therapy for depression, Psychopharmacology Bulletin 24, 183-188 (1988)
108. Jean Thuillier, Ten Years that Changed the Face of Mental Illness, trans. Gordon Hickish (London: Martin Dunitz, 1999)
109. David J. Osborn et al., Relative risk of cardiovascular and cancer mortality in people with serious mental illness from the United Kingdom's General Practice Research Database, Archives of General Psychiatry 64, 1123-1131 (2007)
110. Sukanta Saha, David Chant, and John McGrath, A systematic review of mortality in schizophrenia, Archives of General Psychiatry 64, 1123-1131 (2007)
111. Archibald Cochrane, Effectiveness and Efficiency (London: Nuffield Provincial Hospitals' Trust, 1972)
112. Iain Chalmers, Kay Dickerson, and Thomas C. Chalmers, Getting to grips with Archie Cochrane's Agenda, BMJ 305, 786-788 (1992)
113. David L. Sackett, Brian R. Haynes, Gordon Guyatt, and Peter Tugwell, Clinical Epidemiology: A Basic Science for Clinical Medicine (Boston: Little Brown, 1985)
114. David L. Sackett and William M. Rosenberg, The need for evidence-based medicine, Journal of the Royal Society of Medicine 88, 620-624 (1995)
115. David Healy and Marie Savage, Reserpine exhumed, British Journal of Psychiatry 172, 376-378 (1998)
116. David L. Davies and Michael Shepherd, Reserpine in the treatment of anxious and depressed patients, Lancet 117-121 (1955)
117. Michael Shepherd, "Psychopharmacology: Specific and non-specific," in The Psychopharmacologists, ed. David Healy, 2, 237-257 (London: Arnold, 1998)
118. F. Horace Smirk and E. Garth McQueen, Comparison of rescinamine and reserpine as hypotensive agents, Lancet 115-116 (1955)
119. Douglas C. Wallace, Treatment of hypertension. Hypotensive drugs and mental changes, Lancet 116-117 (1955).
120. Martin H. Teicher, Carol Glod, and Jonathan O. Cole, Emergence of intense suicidal preoccupation during f uoxetine treatment, American Journal of Psychiatry 147, 207-210 (1990)
121. Charles Medawar and Anita Hardon, Medicines Out of Control? (Amsterdam: Aksant, 2004)
122. Austin Bradford Hill, Reflections on the controlled trial, Annals of the Rheumatic Diseases 25, 107-113 (1966)
123. Center Watch, State of the Clinical Trials Industry (Boston: CenterWatch, 2009)
124. Kurt Eichenwald and Gina Kolata, "A doctor's drug studies turn into fraud," New York Times, May 17, 1999.
125. Steve Stecklow and Laura Johannes, "Questions arise on new drug testing. drug makers relied on clinical researchers who now await trial," Wall Street Journal, Aug. 15, 1997.
126. Carl Elliott, "Guinea pigging. Healthy human subjects for drug safety trials are in demand. But is it a living?" New Yorker, 36-41, Jan. 7, 2008.
127. Claire Dyer, Aubrey Blumsohn: Academic who took on industry, BMJ 340, 22-23 (2010)
128. David Healy, Let Them Eat Prozac (New York: New York University Press, 2004)
129. Bruce M. Psaty and Richard A. Kronmal, Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment, JAMA 299, 1813-1817 (2008)
130. Catherine DeAngelis and Phil B. Fontanarosa, Impugning the integrity of medical science: The adverse effects of industry influence, JAMA 299, 1833-1836 (2008)
131. Jon Jureidini, Leemon B. McHenry, and Peter R. Mansfield, Clinical trials and drug promotion: Selective reporting of Study 329, International Journal of Risk and Safety in Medicine 20, 73-81 (2009)
132. Alison Bass, Side Effects (Chapel Hill, NC: Algonquin Books, 2008)
133. Martin D. Keller, Neal D. Ryan, and Michael Strober et al., Efficacy of paroxetine in the treatment of adolescent major depression: A randomized, controlled trial, Journal of the American Academy of Child and Adolescent Psychiatry 40, 762-772 (2001)
134. Louis Sulman, Certain conditions in which a volatile vasoconstrictor has proved of particular value-A preliminary report, Medical Times 63, 374-375 (1935)
135. Nicholas Rasmussen, On Speed: The Many Lives of Amphetamine (New York: New York University Press, 2008)
136. Soma Weiss, Chemical structure: biological action: therapeutic effect, NEJM 220, 906-911 (1939)
137. Louis Lasagna, "Back to the future: Evaluation and drug development 1948-1998," in The Psychopharmacologists, ed. David Healy, 2, 135-166 (London: Arnold, 1998)
138. Sandra Hempel, The Strange Case of the Broad Street Pump: John Snow and the Mystery of Cholera (Berkeley: University of California Press, 2009)
139. Robert Whitaker, Anatomy of an Epidemic (New York: Crown Publishers, 2010)
140. David Michaels, Doubt Is Their Product (New York: Oxford University Press, 2008)
141. James Turk and Jon Thompson, Universities at Risk: How Politics, Special Interests and Corporatization Threaten Academic Integrity (Toronto: Lorimer Press, 2008)
142. Jason Lazarou, Bruce H. Pomeranz, and Paul N. Corey, Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies, JAMA 279, 1200-1205 (1998)
143. Charles M. Beasley et al., Fluoxetine and suicide: A meta-analysis of controlled trials of treatment for depression, BMJ 303, 685-692 (1991)
144. M. N. Graham Dukes and Barbara Schwartz, Responsibility for Drug- Induced Injury (New York: Elsevier, 1988)
145. David Healy, Guest Editorial: A Failure to Warn, International Journal of Risk and Safety in Medicine 12, 151-156 (1999)
146. David Healy, Emergence of antidepressant-induced suicidality, Primary Care Psychiatry 6, 23-28 (2000)
147. Carl Elliott, Introduction, in Prozac as a Way of Life, ed. Carl Elliott and Tod Chambers (Durham, NC: Duke University Press, 2004)
148. P. Kramer, The valorization of sadness: Alienation and melancholic temperament, Hastings Center Report 30, 13-19 (2000)
149. C. Elliott, Pursued by happiness and beaten senseless: Prozac and the American Dream, Hastings Center Report 30, 7-12 (2000)
150. D. DeGrazia, Prozac, enhancement and selfcreation, Hastings Center Report 30, 34-40 (2000)
151. J. C. Edwards, Passion, activity and "the care of the self," Hastings Center Report 30, 31-33 (2000)
152. D. Healy, Good science or good business? Hastings Center Report 30, 19-22 (2000)
153. David Healy and Dinah Cattell, The Interface between authorship, industry and science in the domain of therapeutics, British Journal of Psychiatry 182, 22-27 (2003)
154. Aubrey Blumsohn, http://scientific-misconduct.blogspot.com(accessed Sept. 25, 2006)
155. Jon Jureidini, Leemon B. McHenry, and Peter R. Mansfield, Clinical trials and drug promotion: Selective reporting of Study 329, International Journal of Risk and Safety in Medicine 20, 73-81 (2009)
156. Melanie Newman, The rules of retraction, BMJ 341, 1246-1248 (2010)
157. David Healy, Did regulators fail over selective serotonin reuptake inhibitors? BMJ 333, 92-95 (2006)
158. Catherine De Angelis, The influence of money on medical science, JAMA 296, 996-998 (2006)
159. Cathyrn Clary, Zoloft: Publications Steering Committee Update (July 27, 2000)
160. David Healy and Dinah Cattell, The Interface between authorship, industry and science in the domain of therapeutics, British Journal of Psychiatry 182, 22-27 (2003)
161. L. Duggan et al., Olanzapine for schizophrenia, Cochrane Database of Systematic Reviews Issue 2 (2005), art. no.: CD001359, doi:10.1002/14651858 .CD001359.pub2.
162. Gary D. Tollefson et al., Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression, Journal of Clinical Psychopharmacology 14, 163-169 (1994)
163. Andrew Leon et al., Prospective study of fluoxetine treatment and suicidal behavior in affectively ill subjects, American Journal of Psychiatry 156, 195-201 (1999)
164. Charles B. Nemeroff, Michael T. Compton, and Joseph Berger, The depressed and suicidal patient: Assessment and treatment, Annals of the New York Academy of Science 932, 1-23 (2001)
165. Kimberly A. Yonkers et al., The management of depression during pregnancy: A report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists, General Hospital Psychiatry 31, 403-413 (2009)
166. Herschel S. Jick, James A. Kaye, and Susan Jick, Antidepressants and the risk of suicidal behaviors, JAMA 292, 338-342 (2004)
167. Charles M. Beasley et al., Fluoxetine and suicide: A meta-analysis of controlled trials of treatment for depression, BMJ 303, 685-692 (1991)
168. Robert D. Gibbons et al., The relationship between antidepressant prescription rates and rate of early adolescent suicide, American Journal of Psychiatry 163, 1898-1904 (2006)
169. Gardner Harris, "Senator Grassley seeks financial details from medical groups," New York Times, Dec. 7, 2009, http://www.nytimes.com/2009/12/07/ health/policy/07grassley.html.
170. Duff Wilson, "Medical Schools quizzed on ghostwriting," New York Times, Nov. 17, 2009, http://www.nytimes.com/2009/11/18/business/18ghost.html.
171. Meredith Wadman, The senator's sleuth, Nature 461, 330-334 (2009)
172. Deborah Cohen, Complications: Tracking down the data on oseltamivir, BMJ 339, 1342-1347 (2009)
173. Peter Doshi, Neuraminidase inhibitors: The story behind the Cochrane review, BMJ 339, 1348-1351 (2009)
174. Fiona Godlee, We want raw data now, BMJ 339, 1319 (2009)
175. Andrew Mosholder, Review and evaluation of clinical data, application NDA # 20-272 (11th May 1993)
176. David Healy, The Creation of Psychopharmacology (Cambridge, MA: Harvard University Press, 2002)
177. Richard Harris, The Real Voice (New York: Macmillan, 1964)
178. Robert Rosenheck et al., Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: A randomised controlled trial, JAMA 290, 2693-2702 (2003)
179. Jeffrey A. Lieberman et al., Effectiveness of antipsychotic drugs in patients with chronic schizophrenia, NEJM 353, 1209-1223 (2005)
180. Peter B. Jones et al., Randomized controlled trial of the effect on quality of life of second vs first generation antipsychotic drugs in schizophrenia, Archives of General Psychiatry 63, 1079-1087 (2006)
181. Trevor A. Sheldon and George D. Smith, Consensus conferences as drug promotion, Lancet 341, 100-102 (1993)
182. J. F. Guest, W. M. Hart, R. F. Cookson, and E. Lindstrom, Pharmacoeconomic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia, British Journal of Medical Economics 10, 59-67 (1996)
183. David Healy, Psychopharmacology and the ethics of resource allocation, British Journal of Psychiatry 162, 23-29 (1993)
184. Donald Eccleston, The economic evaluation of antidepressant drug therapy, British Journal of Psychiatry 163, Supplement 20 (1993)
185. Ffion Johnstone, Ian Rickard, and David Healy, The costs of psychotropic medication, British Journal of Psychiatry 167, 112-113 (1995)
186. M. Petersen, "Making drugs, shaping the rules: Big Pharma is eager to help states set medication guidelines," New York Times, Feb. 1, 2004, sec. 3:1, 10.
187. Timothy Kendall, Linsey McGoey, and Emily Jackson, If NICE was in the USA, Lancet, doi:10.10116/5c E (2009)
188. Fiona Godlee, NICE at 10, BMJ 338, 344 (2009)
189. Carroll W. Hughes et al., The Texas children's medication algorithm project: Report of the Texas consensus conference panel on medication treatment of childhood major depressive disorder, Journal of the American Academy of Child and Adolescent Psychiatry 38, 1442-1454 (1999)
190. Rob Waters, "Medicating Aliah," Mother Jones, May/June 2005, 50-55.
191. Duff Wilson, "Poor children likelier to get antipsychotics," New York Times, Dec. 12, 2009, http://www.nytimes.com/2009/12/12/health/12medicaid.html?_r=2&scp=1&sq=antipsychotics&st=cse.
192. David Healy et al., Lifetime suicide rates in treated schizophrenia: 1875-1924 and 1994-1998 cohorts compared, British Journal of Psychiatry 188, 223-228 (2006)
193. Joanna Le Noury et al., The incidence and prevalence of diabetes in patients with serious mental illness in North West Wales: Two cohorts 1875-1924 and 1994-2006 compared. BMC Psychiatry 8, 67 (2008), doi:10.1186/1471-244X-8-67.
194. Jeffrey A. Lieberman et al., Effectiveness of antipsychotic drugs in patients with chronic schizophrenia, NEJM 353, 1209-1223 (2005)
195. Peter B. Jones et al., Randomized controlled trial of the effect on quality of life of second vs first generation antipsychotic drugs in schizophrenia, Archives of General Psychiatry 63, 1079-1087 (2006)
196. David Healy and David Nutt, British Association for Psychopharmacology consensus on statement on childhood and learning disabilities psychopharmacology, Journal of Psychopharmacology 11, 291-294 (1997)
197. Carroll W. Hughes et al., The Texas children's medication algorithm project: Report of the Texas consensus conference panel on medication treatment of childhood major depressive disorder, Journal of the American Academy of Child and Adolescent Psychiatry 38, 1442-1454 (1999)
198. "Depression: 3 million kids suffer from it. What you can do," Newsweek, Oct. 7, 2002, 52-61.
199. Vera H. Sharav, The impact of FDA modernization act on the recruitment of children for research, Ethical Human Sciences and Services 5, 83-108 (2003)
200. Martin D. Keller et al., Efficacy of paroxetine in the treatment of adolescent major depression: A randomized, controlled trial, Journal of the American Academy for Child and Adolescent Psychiatry 40, 762-772 (2001)
201. Graham J. Emslie et al., A double-blind, randomized placebo-controlled trial of fluoxetine in depressed children and adolescents, Archives of General Psychiatry 54, 1031-1037 (1997)
202. Graham J. Emslie et al., Fluoxetine for acute treatment in children and adolescents: A placebo-controlled randomized clinical trial, Journal of the American Academy of Child and Adolescent Psychiatry 41, 1205-1215 (2002)
203. Karen D. Wagner et al., Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: Two randomized controlled trials, JAMA 290, 1033-1041 (2003)
204. W. Kondro, Drug company experts advised staff to withhold data about SSRI use in children, Canadian Medical Association Journal 170, 783 (2004), http://www.healthyskepticism.org/files/docs/gsk/paroxetine/study329/19981014PositionPiece.pdf.
205. Karen D. Wagner et al., A randomized placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents, American Journal of Psychiatry 161, 1079-1083 (2004)
206. A. L. Von Knorring et al., A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder, Journal of Clinical Psychopharmacology 26, 311-315 (2006)
207. Melanie Newman, The rules of retraction, BMJ 341, 1246-1248 (2010)
208. Erick H. Turner et al., Selective publication of antidepressant trials and its influence on apparent efficacy, NEJM 358, 252-260 (2008)
209. Sumant Khanna et al., Risperidone in the treatment of acute mania: Double-blind, placebo-controlled study, British Journal of Psychiatry 187, 229-234 (2005)
210. Sandhya Srinivasan et al., Trial of risperidone in India-concerns, British Journal of Psychiatry 188, 489-492 (2006)
211. P. Colbrook, Can you ignore guidelines? BMJ Careers, 143-144 (April 9, 2005)
212. Tim Croudace et al., Impact of the ICD-10 primary health care (PHC) diagnostic and management guidelines for mental disorders on detection and outcome in primary care: Cluster randomized controlled trial, British Journal of Psychiatry 182, 20-30 (2003)
213. Peter Tyrer, Michael King, and J. Fluxman, Treatment of common mental disorders in general practice: Are current guidelines useless? British Journal of Psychiatry 183, 78 (2003)
214. Edward Evarts, "A discussion of the relevance of effects of drugs on animal behavior to the possible effects of drugs on psychopathological processes in man." in Psychopharmacology: Problems in Evaluation, ed. Jonathan O. Cole and Ralph W. Gerard, 284-306, esp. 302 (Washington, DC: National Academy of Sciences/National Research Council, 1959)
215. David Healy et al., Psychiatric bed utilisation: 1896 and 1996 compared, Psychological Medicine 31, 779-790 (2001)
216. Craig W. Colton and Ronald W. Manderscheid, Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states, Preventing Chronic Disease, 3:2 (2006), http://www.cdc.gov/pcd/issues/2006/apr/05_0180.htm.
217. Urban Osby et al., Time trends in schizophrenia mortality in Stockholm County, Sweden: A cohort study, BMJ 321, 483-484 (2000)
218. Matti Joukamaa, Markku Heliovaara, and Paul Knekt et al., Schizophrenia, neuroleptic medication and mortality, British Journal of Psychiatry 188, 122-127 (2006)
219. David J. Osborn et al., Relative risk of cardiovascular and cancer mortality in people with serious mental illness from the United Kingdom's General Practice Research Database, Archives of General Psychiatry 64, 242-249 (2007)
220. Suhanta Saha, David Chant, and John McGrath, A systematic review of mortality in schizophrenia, Archives of General Psychiatry 64, 1123-1131 (2007)
221. J. J. P. Kastelein et al., Simvastatin with or without Ezetimibe in familial hypercholesterolemia, NEJM 358, 1431-1443 (2008)
222. P. J. Barter et al., Effects of Torcetrapib in patients at high risk for coronary events, NEJM 357, 2109-2122 (2007)
223. ONTARGET, Telmisartan, Ramipril, or both in patients at high risk for vascular events, NEJM 358, 1547-1559 (2008)
224. Steven E. Nissen and Kathy Wolski, Effect of Rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes, NEJM 356, 2457-2471 (2007)
225. Craig J. Currie et al., Survival as a function of HbA1c in people with type 2 diabetes: A retrospective cohort study, Lancet (2010), doi:10.1016/ S0140-6736(09)61969-3.
226. Karen Davis et al., Mirror, Mirror on the Wall: An International Update on the Comparative Performance of American Health Care (Washington, DC: Commonwealth Fund, 2007), http://www.commonwealthfund.org/Content/Publications/Fund-Reports/2007/May.
227. John Abramson, Overdosed America (New York: Harper Perennial, 2005)
228. Thomas Jefferson, Peter Doshi, Matthew Thompson, and Carl Heneghan, Ensuring safe and effective drugs: who can do what it takes? BMJ 342, 148-151 (2011)
229. Doron Garfinkel, Sarah Zur-Gil, and Joshua Ben-Israel, The war against polypharmacy: A new cost-effective geriatric-palliative approach for improving drug therapy in disabled elderly people, Israel Medical Association Journal 9, 430-434 (2007)
230. Doron Garfinkel and Derelie Mangin, Feasibility study of a systematic approach for discontinuation of multiple medications in older adults, Archives of International Medicine 170, 1648-1654 (2010)
231. Neil Pearce, Adverse Reaction: The Fenoterol Story (Aukland: Auckland University Press, 2007)
232. Walter O. Spitzer et al., The use of beta agonists and the risk of death and near death from asthma, NEJM 326, 501-506 (1992)
233. Shelley Salpeter, Nicholas S. Buckley, Thomas M. Ormiston, and Edwin Salpeter, Meta-analysis: Effect of long-acting beta agonist on severe asthma exacerbations and asthma related deaths, Annals of Internal Medicine 144, 904-912 (2006)
234. John Berger, A Lucky Man (Harmondsworth, UK: Penguin Books, 1973)
235. M. Winckler, The Case of Doctor Sachs (New York: Seven Stories Press, 1998)
236. Steven Timmermans and Marc Berg, The Gold Standard: The Challenge of Evidence Based Medicine and Standardization in Health Care (Philadelphia: Temple University Press, 2003)
237. Edward Shorter and David Healy, Shock Therapy (New Brunswick, NJ: Rutgers University Press, 2008)
238. Hillel Schwartz, Never Satisfied: A Cultural History of Diets, Fantasies and Fat (New York: The Free Press, 1986)
239. Theodore Eisenberg and Martin T. Wells, Statins and adverse cardiovascular events in moderate-risk females: A statistical and legal analysis with implications for FDA pre-emption, Journal of Empirical Legal Studies 5, 507-550 (2008)
240. John Abramson, Overdosed America: The Broken Promise of American Medicine (New York: Harper Perennial, 2004)
241. Ramon Estruch et al., Effects of a Mediterranean-style diet on cardiovascular risk factors: A randomized trial, Annals of Internal Medicine 146, 1-11 (2006)
242. Isabelle Savoie and Arminee Kazanjian, Utilization of lipid-lowering drugs in men and women: A reflection of the research evidence, Journal of Clinical Epidemiology 55, 97-98 (2002)
243. Peter S. Sever et al., Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower than average cholesterol concentrations in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid lowering arm (ASCOT-LLA), Lancet 361, 1149-1155 (2003)
244. Colette B. Raymond et al., Population-based analysis of statin utilization in British Columbia, Clinical Therapeutics 29, 2107-2115 (2007)
245. Dudley Gentles et al., Serum lipid levels for a multicultural population in Auckland, New Zealand, New Zealand Medical Journal 120, 1-12 (2008)
246. Gentles et al., Serum lipid levels for a multicultural population in Auckland, New Zealand.
247. Robert A. Wilson, Feminine Forever (New York: M. Evans, 1966)
248. Gillian Sansom, The Myth of Osteoporosis (Ann Arbor, MI: Century Publications, 2003)
249. Elaine S. Berman, Too Little Bone: The Medicalization of Osteoporosis, Journal of Women's Health and Law 1, 257-277 (1999)
250. K. Bassett, "On trying to stop the measurement of bone density to sell drugs," in Tales from the Other Drug Wars, ed. M. L. Barer et al. (Vancouver: Centre for Health Services and Policy Research, 2000)
251. Tamir Ali and Roger H. Jay, Spontaneous femoral shaft fracture after long-term alendronate, Age and Ageing 38, 625-626 (2009)
252. E. E. Roughead, K. McGeehan, and G. P. Sayer, Biphosphonate use and subsequent prescription of acid suppressants, British Journal of Clinical Pharmacology 57, 813-816 (2004)
253. Redonda G. Miller et al., Incidence of gastrointestinal events among biphosphonate patients in an observational setting, American Journal of Managed Care 10, 207-215 (2004)
254. J. J. Wolff et al., The effect of exercise training programs on bone mass: A meta-analysis of published controlled trials in pre and post-menopausal women, Osteoporosis International 9, 1-12 (1999)
255. Max Hamilton, A rating scale for depression, Journal of Neurology, Neurosurgery and Psychiatry 23, 56-62 (1960)
256. Max Hamilton, "Rating Scales in Depression," in Depressive Illness, Diagnosis, Assessment, Treatment, ed. P. Kielholz, 100-108 (Berne: Hanns Huber Publishers, 1972)
257. David Healy, Derelie Mangin, and Barbara Mintzes, The ethics of controlled trials in prenatal depression, International Journal of Risk and Safety in Medicine 22, 1-10 (2010), doi:10.3233/JRS-2010-048.
258. Ray Moynihan and David Henry, The fight against disease mongering: Generating knowledge for action, Public Library of Science Medicine 3 (2006)
259. Leonore Tiefer, Female sexual dysfunction: A case study of disease mongering and activist resistance, Public Library of Science Medicine 3, e178 (2006), doi:10.1371/journalpmed.0030178.
260. Jennifer Berman and Laura Berman, For Women Only (New York: Henry Holt, 2001)
261. Diagnostic and Statistical Manual, Third Edition (Washington, DC: American Psychiatric Association, 1980)
262. Kimberly A. Yonkers et al., The management of depression during pregnancy: A report from the American Psychiatric Association and American College of Obstetricians and Gynecologists, General Hospital Psychiatry 31, 403-413 (2009)
263. Jason Lazarou, Bruce H. Pomeranz, and Paul N. Corey, Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies, JAMA 279, 1200-1205 (1998)
264. Thomas E. Bittker, The industrialization of American psychiatry, American Journal of Psychiatry 142, 149-154 (1985)
265. Philip M. Sinaikin, Categorical diagnosis and a poetics of obligation: An ethical commentary on psychiatric diagnosis and treatment, Ethical Human Sciences and Services 5, 141-148 (2003)
266. Philip M. Sinaikin, Coping with the medical model in clinical practice or "How I learned to stop worrying and love DSM," Journal of Critical Psychology, Counselling and Psychotherapy, 204-213 (2004)
267. Kimberly S. Yarnall, Kathryn I. Pollak, and Truls Ostbye, Primary care: Is there enough time for prevention? American Journal of Public Health 93, 635-641 (2003)
268. Larry Eliot and Daniel Atkinson, The Gods That Failed: How Blind Faith in the Markets Has Cost Us Our Future (London: Bodley Head, 2008)
269. James Spence, The Purpose and Practice of Medicine (Oxford: Oxford University Press, 1960)
270. James Lind, A Treatise of the Scurvy (1752; Edinburgh: Edinburgh University Press, 1953)
271. Mark Bostridge, Florence Nightingale (Harmondsworth, UK: Penguin Books, 2009)
272. L. J. Rather, Collected Essays on Public Health and Epidemiology of Rudolf Virchow (New York: Science History Publications, 1985)
273. Kenneth F. Kiple, Plagues, Pox and Pestilence: Disease in History (London: Weidenfeld and Nicolson, 1997)
274. Richard Harris, The Real Voice (New York: Macmillan Press, 1964), 64.
275. Eric Kimbuende, Usha Ranji, Janet Lundy, and Alina Salganicoff, US Health Care Costs (2010), http://www.kaiseredu.org/topics_im.asp?imID=1&parentID=61&id=358 (accessed May 6, 2011)
276. David Leonhardt, "The choice: A longer life or more stuff," New York Times, Sept. 27, 2006, http://www.nytimes.com/2006/09/27/business/27leonhardt.html (accessed May 9, 2011)
277. Bob Roehr, Healthcare in the US ranks lowest among developed countries, BMJ 337, 889 (2008)
278. Nananda Col, James E. Fanale, and Penelope Kronholm, The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly, Archives of Internal Medicine 150, 841-845 (1990)
279. US Congress, Congressional Budget Office, Technological Change and the Growth of Health Care Spending (Jan. 2008)
280. Padmaja Chalassani, David Healy, Richard Morriss, Presentation and frequency of catatonia in new admissions to two acute psychiatric admission units in India and Wales, Psychological Medicine 35, 1667-1675 (2005)
281. Ray Moynihan and David Henry, Disease Mongering is now part of the global health debate, PLoS Medicine (2008), doi:10.1371/journal .pmed.0050106.
282. Steven Woloshin and Lisa Schwartz, Giving legs to Restless Legs. A case study of how the media makes people sick, PLoS Medicine (2006), doi:10.1371/journal.pmed.0030170.
283. Jerome Groopman, How Doctors Think (New York: Norton, 2007)
284. Jason Lazarou, Bruce Pomeranz, and Paul Corey, Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies, JAMA 279, 1200-1205 (1998)
285. Annemarie Mol, The Logic of Care (London: Routledge, 2008)
286. Michael Bliss, The Discovery of Insulin (Toronto: McClelland and Stewart, 1982)
287. Edward Shorter and David Healy, Shock Therapy (New Brunswick, NJ: Rutgers University Press, 2008)
288. Thomas Hager, The Demon under the Microscope (New York: Harmony Books, 2006)
289. Jeremy A. Greene, Prescribing by Numbers: Drugs and the Definition of Disease (Baltimore: Johns Hopkins University Press, 2007)
290. Louis Lasagna, Congress, the FDA, and new drug development: Before and after 1962, Perspectives in Biology and Medicine 32, 322-343 (1989)
291. John Abrahams, Science, Politics and the Pharmaceutical Industry (London: UCL and St. Martin's Press, 1995)
292. Dwight L. Evans et al., Mood disorders in the medically ill: Scientific review and recommendations, Biological Psychiatry 58, 175-189 (2005)
293. Gabrielle A. Carlson et al., Methodological issues and controversies in clinical trials with child and adolescent patients with bipolar disorder: Report of a consensus conference, Journal of Child and Adolescent Psychopharmacology 13, 13-27 (2003)
294. Peter S. Jensen et al., Consensus report on impulsive aggression as a symptom across diagnostic categories in child psychiatry: Implications for medication studies, Journal of the American Academy of Child and Adolescent Psychiatry 6, 309-322 (2007)
295. Joseph S. Ross et al., Pooled analysis of rofecoxib placebo-controlled clinical trial data: Lessons for postmarketing pharmaceutical surveillance, Archives of Internal Medicine 169, 1976-1984 (2009)
296. Martin H. Teicher, Carol Glod, and Jonathan O. Cole, Emergence of intense suicidal preoccupation during fluoxetine treatment, American Journal of Psychiatry 147, 207-210 (1990)
297. David Healy, The antidepressant tale: Figures signifying nothing? Advances in Psychiatric Treatment 12, 320-328 (2006)
298. Charles M. Beasley et al., Fluoxetine and suicide: A meta-analysis of controlled trials of treatment for depression, BMJ 303, 685-692 (1991)
299. David E. Wheadon et al., Lack of an association between fluoxetine and suicidality in bulimia nervosa, Journal of Clinical Psychiatry 53, 235-241 (1992)
300. David Healy, Did regulators fail over selective serotonin reuptake inhibitors? BMJ 333, 92-95 (2006)
301. Carol Bombardier et al., VIGOR Study Group, Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis, NEJM 343, 1520-1528 (2000)
302. David Armstrong, "Bitter Pill: How the New England Journal missed warning signs on Vioxx. Medical weekly waited years to report flaws in article that praised pain drug," Wall Street Journal, May 15, 2006.
303. Louis Lasagna, "Back to the future: Evaluation and drug development 1956 to 1996," in The Psychopharmacologists, ed. David Healy, 2 (London: Arnold, 1998)
304. Sandor Greenland, Bayesian perspectives for epidemiological research, International Journal of Epidemiology 35, 777-778 (2006)
305. Ezra Hauer, The harm done by tests of significance, Accident Analysis and Prevention 36, 495-500 (2004)
306. Charles Poole, Why published epidemiology is really junk science, Congress of Epidemiology, Toronto, June 13, 2001
307. Kenneth J. Rothman, Writing for Epidemiology, Epidemiology 9, 333-337 (1998)
308. Arif Khan et al., Suicide risk in patients with anxiety disorders; A metaanalysis of the FDA database, Journal of Affective Disorders 68, 183-190 (2002)
309. Arif Khan et al., Suicide rates in clinical trials of SSRIs, other antidepressants and placebo: Analysis of FDA reports, American Journal of Psychiatry 160, 790-792 (2003)
310. Chris Bushe and Richard Holt, Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia, British Journal of Psychiatry (Supplement 47) 184, s67-71 (2004)
311. Joanna Le Noury et al., The incidence and prevalence of diabetes in patients with serious mental illness in North West Wales: Two cohorts 1875-1924 and 1994-2006 compared, BMC Psychiatry 8, 67 (2004), doi:10.1186/1471-244X-8-67.
312. Barry G. Firkin and J. A. Whitworth, Dictionary of Medical Eponyms (Carnforth, UK: Parthenon Publishing, 1987)
313. David Michaels, Doubt Is Their Product (New York: Oxford University Press, 2008)
314. Parents Med Guide, The use of medication in treating childhood and adolescent depression: Information for patients and families, prepared by the American Psychiatric Association and American Academy of Child and Adolescent Psychiatry (2005), http://www.ParentsMedGuide.org (accessed Feb. 1, 2005)
315. David Sheahan, "Angles on panic," in The Psychopharmacologists, ed. David Healy, 3, 479-504 (London: Arnold, 2000)
316. The Tobacco Institute Inc., Tobacco and the Health of the Nation (San Francisco: Legacy of Tobacco Documents Library, UCSF, 1969), http:// legacy.library.ucsf.edu/cgi/getdoc?tid=dxb34f00&fmt=pdf&ref=results.
317. Goran Isacsson et al., Decrease in suicides among the individuals treated with antidepressants: A controlled study of antidepressants in suicide, Sweden 1995-2005, Acta Psychiatrica Scandinavia 120, 37-44 (2009)
318. Svein Reseland et al., National suicide rates 1961-2003: Further analysis of Nordic data for suicide, autopsies and ill-defined death rates, Psychotherapy and Psychosomatics 77, 78-82 (2008)
319. Greg D. Curfman, Stephen Morrissey, and Jeffrey Drazen, Why doctors should worry about pre-emption, NEJM 359, 1-3 (2009)
320. Clifford J. Rosen, The Rosiglitazone story: Lessons from an FDA advisory committee, NEJM 357, 844-846 (2007), 1056/nejmp078167.
321. Steven Nissen and Kathy Wolski, Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes, NEJM 356, 2457-2471 (2007)
322. Deborah Cohen, Rosiglitazone: What went wrong? BMJ 341, 530-534, c4848 (2010)
323. Philip D. Home et al., Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial, Lancet 373, 2125-2135 (2009)
324. Adrienne Fugh-Berman et al., Promotional tone in reviews of menopausal hormone therapy after the women's health initiative: An analysis of published articles, Public Library of Science Medicine 8, e1000425 (2011)
325. Annemarie Mol, The Logic of Care (London: Routledge, 2008)
326. Samuel Sessions and Alan Detsky, The "Shadow Government" in Health Care, JAMA 304, 2742-2743 (2010)
327. Steven J. Gould. The Mismeasure of Man (Harmondsworth, UK: Penguin Books, 1980)
328. Joseph S. Ross et al., Pooled analysis of rofecoxib placebo-controlled clinical trial data: Lessons for postmarketing pharmaceutical surveillance, Archives of Internal Medicine 169, 1976-1984 (2009)
329. Philip Fine, Make Big Pharma provide their raw data, University World News, Jan. 18, 2009, http://www.universityworldnews.com/article.php?story=20090115191615198.
330. Jon Thompson, Patricia Baird, and Jocelyn Downie, The Olivieri Report (Toronto: Lorimer, 2001)
331. David Healy, Derelie Mangin, and Barbara Mintzes, The ethics of controlled trials in prenatal depression, International Journal of Risk and Safety in Medicine 22, 1-10 (2010), doi:10.3233/JRS-2010-048.
332. Geoffrey Venning, Validity of anecdotal reports of suspected adverse drug reactions: The problem of false alarms, BMJ 284, 249-253 (1982)
333. David Healy and Dinah Cattell, The Interface between authorship, industry and science in the domain of therapeutics, British Journal of Psychiatry 182, 22-27 (2003)
334. Erick H. Turner et al., Selective publication of antidepressant trials and its influence on apparent efficacy, NEJM 358, 252-260 (2008)
335. Gonzalo Laje et al., Genetic markers of suicidal ideation emerging during citalopram treatment of major depression, American Journal of Psychiatry 164, 1530-1538 (2007)
336. R. Bordet et al., Analysis of the direct cost of adverse drug reactions in hospitalised patients, European Journal of Clinical Pharmacology, 56, 935-941 (2001), doi:10.1007/s002280000260.
337. Richard J. Wurtman and R. L. Bettiker, The slowing of treatment discovery, 1965-1995, Nature Medicine 1, 1122-1125 (1995)
338. Paul R. Gross and Norman Levitt, Higher Superstition: The academic left and its quarrel with science (Baltimore: Johns Hopkins University Press, 1994)
339. Ivan Illich, Limits to Medicine (Medical Nemesis) (Harmondsworth, UK: Penguin Books, 1976)
340. John Abramson, Overdosed America: The Broken Promise of American Medicine (New York: Harper Perennial, 2005)
341. Gardiner Harris, "Senator Grassley seeks financial details from medical groups," New York Times, Dec. 7, 2009, http://www.nytimes.com/2009/12/07/health/policy/07grassley.html.
342. Meredith Wadman, The senator's sleuth, Nature 461, 330-334 (Sept. 17, 2009)
343. Sandra Hempel, The Strange Case of the Broad Street Pump: John Snow and the Mystery of Cholera (Berkeley: University of California Press, 2009)
344. Dwight D. Eisenhower, Military industrial complex speech (1961), http:// www.cnn.com/SPECIALS/cold.war/episodes/12/documents/eisenhower.speech (accessed April 21, 2002)
345. Kenneth Kiple, Plagues, Pox and Pestilence (London: Weidenfield and Nicholson, 1997)
346. Hank McKinnell, A Call to Action (New York: McGraw Hill, 2005)